Awakn Life Sciences Corp C.AWKN

Alternate Symbol(s): AWKNF

Healthcare Biotechnology

Awakn Life Sciences Corp. is a Canada-based biotechnology company. The Company is engaged in the research, development, and commercializing of therapeutics to treat addiction with a focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company operates through three segments: development, delivery and corporate. The development segment, which focuses on researching and developing psychedelic drugs and therapies, ketamine-assisted psychotherapy and methylenedioxy-methamphetamine (MDMA)-assisted psychotherapy to treat substance and behavioral addictions. The delivery segment, which includes a chain of medical psychedelic clinics across Europe. The Company operates in the United Kingdom (UK), Ireland and Canada.

CSE:AWKN - Post by User

Awakn Life Sciences Corp

<< Previous

Bullboard Posts

Next >>

Post by Betteryear2on Apr 06, 2022 3:42pm

145 Views

Post# 34581791

Successfully Complete Phase One of Its Drug Discovery Prog.

Two Chemical Series Identified to Facilitate Lead Optimisation Activities

Toronto, Ontario--(Newsfile Corp. - April 6, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering revolutionary therapeutics to treat addiction, announced today the successful completion of phase one of its new chemical entity (NCE) development program, strengthening Awakn's pipeline for the treatment of a broad range of both substance and behavioural addictions.

Awakn Successfully Completes Phase One of Its Drug Discovery Program

<< Previous

Bullboard Posts

Next >>

Cloud DX among leading remote patient monitoring suppliers in Canada